Journal Article

Cancer germline predisposing variants and late mortality from subsequent malignant neoplasms among long-term childhood cancer survivors: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study

Wang, Mingjuan, Tithi, Saima Sultana, Shelton, Kyla, Plonski, Noel-Marie, Hudson, Melissa M, Howell, Rebecca, Leisenring, Wendy M, Song, Nan, Easton, John, Zhang, Jinghui, Chen, Wenan, Qin, Na, Chen, Cheng, Wu, Gang, Ehrhardt, Matthew J, Mulder, Heather L, Robison, Leslie L, Kennetz, Dennis, Nichols, Kim E, Bhatia, Smita, Ness, Kirsten K, Edmonson, Michael N, Wang, Hui, Srivastava, Deo Kumar, Hui, Yawei, Rusch, Michael C, Yasui, Yutaka, Dong, Qian, Thrasher, Andrew, Im, Cindy, Wang, Zhaoming, Stratton, Kayla L, Armstrong, Gregory T

2023

Overview

Carriers of cancer predisposing variants are at an increased risk of developing subsequent malignant neoplasms among those who have survived childhood cancer. We aimed to investigate whether cancer predisposing variants contribute to the risk of subsequent malignant neoplasm-related late mortality (5 years or more after diagnosis). In this analysis, data were included from two retrospective cohort studies, St Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS), with prospective follow-up of patients who were alive for at least 5 years after diagnosis with childhood cancer (ie, long-term childhood cancer survivors) with corresponding germline whole genome or whole exome sequencing data. Cancer predisposing variants affecting 60 genes associated with well-established autosomal-dominant cancer-predisposition syndromes were characterised. Subsequent malignant neoplasms were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 with modifications. Cause-specific late mortality was based on linkage with the US National Death Index and systematic cohort follow up. Fine-Gray subdistribution hazard models were used to estimate subsequent malignant neoplasm-related late mortality starting from the first biospecimen collection, treating non-subsequent malignant neoplasm-related deaths as a competing risk, adjusting for genetic ancestry, sex, age at diagnosis, and cancer treatment exposures. SJLIFE (NCT00760656) and CCSS (NCT01120353) are registered with ClinicalTrials.gov. 12 469 (6172 male and 6297 female) participants were included, 4402 from the SJLIFE cohort (median follow-up time since collection of the first biospecimen 7·4 years [IQR 3·1–9·4]) and 8067 from the CCSS cohort (median follow-up time since collection of the first biospecimen 12·6 years [2·2–16·6]). 641 (5·1%) of 12 469 participants carried cancer predisposing variants (294 [6·7%] in the SJLIFE cohort and 347 [4·3%] in the CCSS cohort), which were significantly associated with an increased severity of subsequent malignant neoplasms (CTCAE grade ≥4 vs grade <4: odds ratio 2·15, 95% CI 1·18–4·19, p=0·0085). 263 (2·1%) subsequent malignant neoplasm-related deaths (44 [1·0%] in the SJLIFE cohort; and 219 [2·7%] in the CCSS cohort) and 426 (3·4%) other-cause deaths (103 [2·3%] in SJLIFE; and 323 [4·0%] in CCSS) occurred. Cumulative subsequent malignant neoplasm-related mortality at 10 years after the first biospecimen collection in carriers of cancer predisposing variants was 3·7% (95% CI 1·2–8·5) in SJLIFE and 6·9% (4·1–10·7) in CCSS versus 1·5% (1·0–2·1) in SJLIFE and 2·1% (1·7–2·5) in CCSS in non-carriers. Carrying a cancer predisposing variant was associated with an increased risk of subsequent malignant neoplasm-related mortality (SJLIFE: subdistribution hazard ratio 3·40 [95% CI 1·37–8·43]; p=0·0082; CCSS: 3·58 [2·27–5·63]; p<0·0001). Identifying participants at increased risk of subsequent malignant neoplasms via genetic counselling and clinical genetic testing for cancer predisposing variants and implementing early personalised cancer surveillance and prevention strategies might reduce the substantial subsequent malignant neoplasm-related mortality burden. American Lebanese Syrian Associated Charities and US National Institutes of Health.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Cancer Survivors / Cancer therapies / Chemotherapy / Child / Childhood / Children / Children & youth / Classification / Cohort analysis / Diagnosis / Disease prevention / Female / Follow-Up Studies / Genetic counseling / Genetic screening / Genomes / Hematology, Oncology, and Palliative Medicine / Humans / Male / Medical diagnosis / Medical records / Mortality / Neoplasia / Neoplasms - pathology / Prospective Studies / Radiation therapy / Retrospective Studies / Review boards / Risk Factors / Self report / Survivor / Terminology / Tumors